Bone marrow vs extramedullary relapse of acute leukemia after allogeneic hematopoietic cell transplantation: Risk factors and clinical course

Bone Marrow Transplantation

Volumn 32, Issue 8, 2003, Pages 835-842

  Lee, K H ^a   Lee, J H ^a   Choi, S J ^a   Kim, S ^a   Seol, M ^a   Lee, Y S ^a   Kim, W K ^a   Seo, E J ^a   Park, C J ^a   Chi, H S ^a   Lee, J S ^a  

^a University of Ulsan   (South Korea)

Author keywords

Acute leukemia; Allogeneic HCT; Extramedullary relapse

Indexed keywords

ANTINEOPLASTIC AGENT; BUSULFAN; CYCLOPHOSPHAMIDE; CYCLOSPORIN; FLUDARABINE; FLUDARABINE PHOSPHATE; GRANULOCYTE COLONY STIMULATING FACTOR; IMATINIB; METHOTREXATE; METHYLPREDNISOLONE; THYMOCYTE ANTIBODY;

ACUTE GRANULOCYTIC LEUKEMIA; ACUTE LEUKEMIA; ACUTE LYMPHOCYTIC LEUKEMIA; ADULT; ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION; ARTICLE; BLADDER METASTASIS; BONE MARROW METASTASIS; BRAIN METASTASIS; BREAST METASTASIS; CANCER COMBINATION CHEMOTHERAPY; CANCER LOCALIZATION; CANCER RECURRENCE; CANCER RISK; CELL LINEAGE; CONTROLLED STUDY; DISEASE ACTIVITY; DISEASE COURSE; FEMALE; FOLLOW UP; GRAFT VERSUS HOST REACTION; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; INTESTINE CANCER; MAJOR CLINICAL STUDY; MALE; MEDIASTINUM METASTASIS; MENINGEAL METASTASIS; PANCREAS CANCER; PATHOGENESIS; PHILADELPHIA CHROMOSOME POSITIVE CELL; PLEURA METASTASIS; PREDICTION; PRIORITY JOURNAL; RISK FACTOR; SKIN METASTASIS; SOFT TISSUE METASTASIS; SPINE METASTASIS; URINARY TRACT CANCER; UTERUS CANCER;

ACUTE DISEASE; ADOLESCENT; ADULT; BONE MARROW DISEASES; BONE MARROW TRANSPLANTATION; FEMALE; FOLLOW-UP STUDIES; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; LEUKEMIA; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; PREDICTIVE VALUE OF TESTS; RECURRENCE; RISK FACTORS; SURVIVAL RATE; TRANSPLANTATION, HOMOLOGOUS;

EID: 11144357836     PISSN: 02683369     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.bmt.1704223     Document Type: Article

References (35)

1. Giralt SA, Champlin RE. Leukemia relapse after allogeneic bone marrow transplantation: A review. Blood 1994; 84: 3603-3612.
2. Zittoun RA, Mandelli F, Willemze R et al. Autologous or allogeneic bone marrow transplantation compared with intensive chemotherapy in acute myelogenous leukemia. N Engl J Med 1995; 332: 217-223.
3. Horowitz MM, Messerer D, Hoelzer D et al. Chemotherapy compared with bone marrow transplantation for adults with acute lymphoblastic leukemia in first remission. Ann Intern Med 1991; 115: 13-18.
4. Au WY, Kwong YL, Lie AKW et al. Review article. Extramedullary relapse of leukemia following allogeneic bone marrow transplantation. Hematol Oncol 1999; 17: 45-52.
5. Chong G, Byrnes G, Szer J, Grigg A. Extramedullary relapse after allogeneic bone marrow transplantation for haematological malignancy. Bone Marrow Transplant 2000; 26: 1011-1025.
6. Lee K-H, Lee J-H, Kim S et al. High frequency of extramedullary relapse of acute leukemia after allogeneic bone marrow transplantation. Bone Marrow Transplant 2000; 26: 147-152.
7. Simpson DR, Nevill TJ, Shepherd JD et al. High incidence of extramedullary relapse of AML after busulfan/cyclophosphamide conditioning and allogeneic stem cell transplantation. Bone Marrow Transplant 1998; 22: 259-264.
8. Békássy AN, Hermans J, Gorin NC, Gratwohl A. Granulocytic sarcoma after allogeneic bone marrow transplantation: A retrospective European multicenter survey. Bone Marrow Transplant 1996: 17: 801-808.
9. De la Cámara R, Figuera A, Steegmann JL et al. Allogeneic bone marrow transplantation for high risk acute lymphoblastic leukemia. Results from a single institution. Bone Marrow Transplant 1992; 9: 433-438.
10. Oliff A, Ramu N-P, Poplack D. Leukemic relapse 5 1/2 years after allogeneic bone marrow transplantation. Blood 1978; 52: 281-284.
11. Lawson SE, Darbyshire PJ. Use of donor lymphocytes in extramedullary relapse of childhood acute lymphoblastic leukaemia following bone marrow transplantation. Bone Marrow Transplant 1998; 22: 829-830.
12. Colombini A, Barzaghi A, Castagneto M et al. Retro-orbital late relapse in a child with leukemia after allogeneic bone marrow transplantation. Acta Haematol 1995; 94: 44-47.
13. Fleming DR, Greenwood MF, Garrison J et al. Lymphocyte infusion for delayed extramedullary relapse of acute leukemia following bone marrow transplantation. Leuk Lymphoma 1996; 21: 525-528.
14. Schäfer H, Bader P, Kaiserling E et al. Extramedullary relapses at uncommon sites after allogeneic stem cell transplantation. Bone Marrow Transplant 2000; 26: 1133-1134.
15. Kelch BP, Bulova SI, Crilley P et al. An unusual extramedullary relapse of acute nonlymphocytic leukemia after allogeneic bone marrow transplantation. Am J Clin Oncol 1990; 13: 238-243.
16. Au WY, Lie AKW, Liang R, Kwong YL. Isolated extramedullary relapse of acute lymphoblastic leukemia after allogeneic bone marrow transplantation. Bone Marrow Transplant 1999; 24: 1137-1140.
17. Forrest DL, Dalal BI, Naiman SC et al. Testicular relapse of acute promyelocytic leukemia after allogeneic BMT. Bone Marrow Transplant 1997; 20: 689-690.
18. Ueda S, Kanamori H, Sasaki S et al. Isolated extramedullary relapse in knee joint after allogeneic bone marrow transplantation for Ph ALL. Bone Marrow Transplant 1998; 21: 319-321.
19. Riseberg DA, Mulvey KP, Dahut WL et al. Late extramedullary relapse following bone marrow transplant for AML presenting as acute renal failure and leukemic ascites. Bone Marrow Transplant 1994; 14: 1009-1010.
20. Michel G, Boulad F, Small TN et al. Risk of extramedullary relapse following allogeneic bone marrow transplantation for acute myelogenous leukemia with leukemia cutis. Bone Marrow Transplant 1997; 20: 107-112.
21. Lee J-H, Lee K-H, Lee J-H et al. Plasminogen activator inhibitor-1 is an independent diagnostic marker as well as severity predictor of hepatic veno-occlusive disease after allogeneic bone marrow transplantation in adults conditioned with busulfan and cyclophosphamide. Br J Hematol 2002; 118: 1087-1094.
22. Lee K-H, Lee J-H, Lee J-H et al. Non-myeloablative conditioning regimen of fludarabine, busulfan, anti-thymocyte globulin, and methylprednisolone for allogeneic peripheral blood hematopoietic cell transplantation. Haematologica 2001; 86: 999-1001.
23. Przepiorka D, Weisdorf D, Martin P et al. Meeting report. Consensus conference on acute GVHD grading. Bone Marrow Transplant 1995; 15: 825-828.
24. Sullivan KM. Acute and chronic graft-versus-host disease in man. Int J Cell Cloning 1986; 4: 42-93.
25. McDonald GB, Hinds MS, Fisher LD et al. Veno-occlusive disease of the liver and multiorgan failure after bone marrow transplantation: A cohort study of 355 patients. Ann Intern Med 1993; 118: 255-267.
26. Bearman SI, Anderson GL, Mori M et al. Venoocclusive disease of the liver: Development of a model for predicting fatal outcome after marrow transplantation. J Clin Oncol 1993; 11: 1729 1736.
27. Choi S-J, Lee K-H, Lee J-H et al. Prognostic value of hematopoietic chimerism in patients with acute leukemia after allogeneic bone marrow transplantation: A prospective study. Bone Marrow Transplant 2000; 26: 327-332.
28. Slovak ML, Kopecky KJ, Cassileth PA et al. Karyotypic analysis predicts outcome of preremission and postremission therapy in adults acute myeloid leukemia: A Southwest Oncology Group/Eastern Cooperative Oncology Group study. Blood 2000; 96: 4075-4083.
29. Lee S, Kim D-W. Kim Y-J et al. Influence of karyotype on outcome of allogeneic bone marrow transplantation for adults with precursor B-lineage acute lymphoblastic leukaemia in first or second remission. Br J Hematol 2002; 117: 109-118.
30. Cornelissen JJ, Carston M, Kollman C et al. Unrelated marrow transplantation for adult patients with poor-risk acute lymphoblastic leukemia: Strong graft-versus-leukemia effect and risk factors determining outcome. Blood 2001; 97: 1572-1577.
31. Hassan M, Ljungman P, Bolme P et al. Busulfan bioavailability. Blood 1994; 84: 2144-2150.
32. Vassal G, Koscielny S, Challine D et al. Busulfan disposition and hepatic veno-occlusive disease in children undergoing bone marrow transplantation. Cancer Chemother Pharmacol 1996; 37: 247-253.
33. Blaise D, Maraninchi D, Archimbaud E et al. Allogeneic bone marrow transplantation for acute acute myeloid leukemia in first remission: A randomized trial of a busulfan-cytoxan versus cytoxan-total body irradiation as preparative regimen: A report from the Groupe d'Etudes de la Greffe de Moelle Osseuse. Blood 1992; 79: 2578-2582.
34. Ringdén O, Ruutu T, Remberger M et al. A randomized trial comparing busulfan with total body irradiation as conditioning in allogeneic marrow transplant recipients with leukemia: A report for the Nordic Bone Marrow Transplantation Group. Blood 1994; 83: 2723-2730.
35. Andersson B, Madden T, Tran HT et al. Acute safety and pharmacokinetics of intravenous busulfan when used with oral busulfan and cyclophosphamide as pretransplantation conditioning therapy: A phase I study. Biol Blood Marrow Transplant 2000; 6: 548-554.